Date: 2016-01-25
Type of information: Nomination
Compound:
Company: Acadia Pharmaceuticals (USA - CA)
Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 25, 2016, Acadia Pharmaceuticals announced the appointment of James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. Dr. Owen will be responsible for evolving and executing the clinical development programs for Acadia’s product candidates and report to Serge Stankovic, M.D., M.S.P.H., Acadia’s Executive Vice President, Head of Research and Development. Dr. Owen most recently served as Vice President, U.S. Clinical Affairs at Lundbeck LLC from 2010 to 2016. During his tenure, his team of medical experts and scientists made significant contributions in drug development across a wide range of neurological and psychiatric disorders, including innovative development programs in schizophrenia, Alzheimer’s disease and stroke, as well as pediatric and adult orphan indications. Prior to joining Lundbeck, Dr. Owen served as Group Director, Global Clinical Research at Bristol-Myers Squibb Company where he co-led the life-cycle management of Abilify® during a period of product extensions in psychiatric indications in the United States and Europe. Dr. Owen received his B.A. at Haverford College and his M.D. at East Tennessee State University, Quillen College of Medicine. He completed his residency at Emory University and is board certified in psychiatry.
Financial terms:
Latest news:
